Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Multiple Myeloma | 6 | 2025 | 291 | 2.200 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2025 | 881 | 0.860 |
Why?
|
| Fertility Preservation | 1 | 2025 | 53 | 0.850 |
Why?
|
| Ribosomes | 1 | 2025 | 191 | 0.810 |
Why?
|
| Patient Navigation | 1 | 2025 | 104 | 0.770 |
Why?
|
| Optical Tweezers | 1 | 2022 | 21 | 0.740 |
Why?
|
| Microfluidics | 1 | 2022 | 62 | 0.710 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2025 | 449 | 0.710 |
Why?
|
| Protein Biosynthesis | 2 | 2025 | 458 | 0.710 |
Why?
|
| Protein Synthesis Inhibitors | 1 | 2020 | 48 | 0.640 |
Why?
|
| Referral and Consultation | 1 | 2025 | 851 | 0.560 |
Why?
|
| Nanopores | 2 | 2025 | 10 | 0.440 |
Why?
|
| Interferon Regulatory Factors | 2 | 2024 | 44 | 0.370 |
Why?
|
| Proto-Oncogene Proteins c-myc | 2 | 2024 | 167 | 0.340 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 1953 | 0.330 |
Why?
|
| Neoplasms | 1 | 2025 | 2875 | 0.290 |
Why?
|
| Osteolysis | 1 | 2025 | 16 | 0.220 |
Why?
|
| Immunoglobulin Light Chains | 1 | 2025 | 51 | 0.220 |
Why?
|
| Peripartum Period | 1 | 2024 | 19 | 0.210 |
Why?
|
| Ikaros Transcription Factor | 1 | 2024 | 23 | 0.210 |
Why?
|
| Thalidomide | 1 | 2024 | 43 | 0.210 |
Why?
|
| Organoids | 1 | 2025 | 141 | 0.200 |
Why?
|
| Microsatellite Repeats | 1 | 2024 | 157 | 0.200 |
Why?
|
| Extracellular Vesicles | 1 | 2025 | 171 | 0.190 |
Why?
|
| Zika Virus | 1 | 2024 | 132 | 0.190 |
Why?
|
| Zika Virus Infection | 1 | 2024 | 168 | 0.180 |
Why?
|
| Health Status Disparities | 1 | 2024 | 321 | 0.170 |
Why?
|
| Cardiomyopathies | 1 | 2024 | 338 | 0.160 |
Why?
|
| Proteasome Inhibitors | 1 | 2020 | 40 | 0.160 |
Why?
|
| Cell Line, Tumor | 2 | 2025 | 3540 | 0.160 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2020 | 191 | 0.160 |
Why?
|
| Primary Cell Culture | 1 | 2020 | 173 | 0.160 |
Why?
|
| Drug Synergism | 1 | 2020 | 357 | 0.150 |
Why?
|
| Genetic Variation | 1 | 2024 | 983 | 0.150 |
Why?
|
| Bone Marrow | 1 | 2020 | 304 | 0.150 |
Why?
|
| Tumor Cells, Cultured | 1 | 2020 | 919 | 0.140 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2024 | 917 | 0.140 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2020 | 928 | 0.130 |
Why?
|
| Antibodies, Monoclonal | 2 | 2023 | 1519 | 0.120 |
Why?
|
| Animals | 5 | 2025 | 38058 | 0.110 |
Why?
|
| Mice | 2 | 2025 | 18339 | 0.110 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 2016 | 131 | 0.110 |
Why?
|
| Humans | 11 | 2025 | 144759 | 0.110 |
Why?
|
| Sputum | 1 | 2016 | 308 | 0.110 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2020 | 1137 | 0.100 |
Why?
|
| Brain | 1 | 2025 | 2933 | 0.100 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2016 | 334 | 0.090 |
Why?
|
| Retrospective Studies | 3 | 2025 | 17066 | 0.090 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2025 | 1455 | 0.070 |
Why?
|
| Young Adult | 1 | 2025 | 14105 | 0.070 |
Why?
|
| Signal Transduction | 1 | 2020 | 5226 | 0.060 |
Why?
|
| Phosphopyruvate Hydratase | 1 | 2025 | 26 | 0.060 |
Why?
|
| Sensitivity and Specificity | 2 | 2024 | 1985 | 0.060 |
Why?
|
| Mustelidae | 1 | 2024 | 2 | 0.060 |
Why?
|
| Adult | 2 | 2025 | 40449 | 0.050 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2024 | 39 | 0.050 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 2024 | 83 | 0.050 |
Why?
|
| ADP-ribosyl Cyclase 1 | 1 | 2023 | 43 | 0.050 |
Why?
|
| North America | 1 | 2024 | 310 | 0.050 |
Why?
|
| Genetics, Population | 1 | 2024 | 214 | 0.050 |
Why?
|
| Canada | 1 | 2024 | 428 | 0.050 |
Why?
|
| Primates | 1 | 2024 | 132 | 0.050 |
Why?
|
| Middle Aged | 1 | 2025 | 35875 | 0.050 |
Why?
|
| Sequence Analysis, RNA | 1 | 2025 | 442 | 0.050 |
Why?
|
| Female | 3 | 2025 | 78271 | 0.050 |
Why?
|
| Single-Cell Analysis | 1 | 2025 | 358 | 0.040 |
Why?
|
| RNA, Viral | 1 | 2024 | 688 | 0.040 |
Why?
|
| Genotype | 1 | 2024 | 1833 | 0.040 |
Why?
|
| Ecosystem | 1 | 2024 | 589 | 0.040 |
Why?
|
| DNA-Binding Proteins | 1 | 2025 | 1499 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2025 | 2832 | 0.030 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2016 | 53 | 0.030 |
Why?
|
| Prognosis | 1 | 2025 | 4282 | 0.030 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2016 | 104 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2016 | 341 | 0.030 |
Why?
|
| DNA, Bacterial | 1 | 2016 | 342 | 0.030 |
Why?
|
| Specimen Handling | 1 | 2016 | 186 | 0.030 |
Why?
|
| Pregnancy | 1 | 2024 | 7190 | 0.020 |
Why?
|
| Mass Screening | 1 | 2016 | 1347 | 0.020 |
Why?
|
| Male | 2 | 2025 | 72315 | 0.020 |
Why?
|
| United States | 1 | 2024 | 15966 | 0.020 |
Why?
|